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The effect of c-reactive Protein 
isoforms on nitric Oxide Production 
by U937 Monocytes/Macrophages
Nicola R. Sproston, Mohamed El Mohtadi, Mark Slevin, William Gilmore  
and Jason J. Ashworth*
School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom
Inflammation is regulated by many endogenous factors including estrogen, a steroid hor-
mone that declines with increasing age, leading to excessive inflammation in the elderly. 
C-reactive protein (CRP) is an acute phase inflammatory protein that exists in two forms, 
native CRP (nCRP) and monomeric CRP (mCRP), which mediate distinct biological activi-
ties. It is unclear how each CRP isoform mediates nitric oxide (NO), a signaling molecule 
generated by NO synthase (NOS). This study investigated whether CRP isoforms have 
distinct effects on NO production by unstimulated and lipopolysaccharide (LPS)-activated 
monocytes/macrophages and whether estrogen mediates CRP-induced NO production 
in an in vitro model of aging. NO and inducible NOS (iNOS) were measured (n = 12) by 
the Griess assay and an enzyme-linked immunosorbent assay, respectively following 
incubation (24 h) of human-derived U937 monocytes/macrophages with CRP isoforms 
[(nCRP) = 500 and 1,000 µg/ml; (mCRP) = 100 and 250 µg/ml] in the absence or pres-
ence of 17 beta-estradiol (1 × 10−7, 1 × 10−8, and 1 × 10−9 M). The response to each CRP 
isoform and estrogen was dependent on the differentiation and activation status of cells. 
Monocytes with or without prior LPS-activation significantly increased (P < 0.01) NO/
iNOS production when treated with mCRP. The mCRP isoform had no effect (P > 0.05) 
on NO/iNOS production by unactivated or LPS-activated macrophages, whereas nCRP 
significantly (P < 0.05) reduced NO/iNOS production by macrophages, with or without 
prior LPS-activation. The nCRP isoform had opposing actions on monocytes, signifi-
cantly (P < 0.01) increasing and reducing NO/iNOS by unactivated and LPS-activated 
monocytes, respectively. Estrogen significantly (P < 0.01) reversed nCRP-mediated NO 
inhibition by unactivated macrophages but decreased CRP-induced NO by unactivated 
monocytes treated with nCRP or mCRP and LPS-activated monocytes treated with 
mCRP. NO was differentially mediated by CRP isoforms in a cell-type/state-specific man-
ner, with production corresponding to concomitant changes in iNOS levels. Collectively, 
the findings indicate nCRP and estrogen predominantly reduce NO production, whereas 
mCRP increases NO production. This supports growing evidence that mCRP exacer-
bates inflammation while nCRP and estrogen dampen the overall inflammatory response. 
Therapeutic strategies that restore estrogen levels to those found in youth and promote 
the stability of nCRP or/and prevent the formation of mCRP may reduce NO production 
in age-related inflammatory conditions.
Keywords: c-reactive protein, nitric oxide, inflammation, native c-reactive protein, monomeric c-reactive protein, 
estrogen
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inTrODUcTiOn
There is increasing evidence that C-reactive protein (CRP) may 
play a role in inflammatory processes. CRP is a homopenta-
meric acute-phase inflammatory protein that exhibits elevated 
expression during inflammatory conditions, such as rheumatoid 
arthritis, some cardiovascular diseases, and infection (1). The 
pentameric protein, termed native CRP (nCRP) is characterized 
by a discoid configuration of five identical non-covalently bound 
subunits, each 206 amino acids long with a molecular mass of 
about 23 kDa (1).
The nCRP isoform is synthesized primarily in liver hepatocytes 
but has also been reported to be synthesized in other cell types, 
such as smooth muscle cells (2), macrophages (3), endothelial 
cells (4), lymphocytes (5), and adipocytes (6). CRP is first syn-
thesized as monomers and then assembled into the pentamer 
in the endoplasmic reticulum of the cell. The stimulation of 
CRP synthesis mainly occurs in response to pro-inflammatory 
cytokines, most notably interleukin-6 (IL-6), IL-1, and tumor 
necrosis factor-alpha (TNF-α) (7,8).
Pentameric CRP can irreversibly dissociate, with the 
resultant-free subunits termed monomeric (or modified) CRP 
(mCRP). The mCRP isoform is distinguished from nCRP by its 
distinct antigenic, biological, and electrophoretic activities (9) 
and the fact it expresses different neoepitopes (10). Evidence 
suggests nCRP which often exhibits a more anti-inflammatory 
function in tissues relative to the mCRP isoform. It is suggested 
that this occurs by nCRP binding at sites of tissue injury to limit 
the generation of the membrane attack complex (MAC) and 
C5a, thus inhibiting complement activation (11). On the other 
hand, mCRP generally has marked pro-inflammatory properties 
in vitro and in vivo by promoting the recruitment of circulating 
leukocytes to areas of inflammation through interaction with 
receptors of the Fcγ family (12) and lipid raft microdomains in 
cell membranes (13).
There has been some evidence that CRP interacts with nitric 
oxide (NO), a short-lived, pleiotropic-free radical regulator of 
various biological functions, including vasodilation, neurotrans-
mission, inflammation, and macrophage-mediated immunity 
(14). NO has properties that allow it to be easily soluble and 
diffuse across biological membranes to conduct its intracellular 
processes (15). This intercellular signaling molecule is important 
for the immune system, as well as generating free oxygen radicals 
called peroxynitrites (ONOO−) which act in a cytotoxic man-
ner causing tissue damage and apoptosis (16). NO also plays 
a functional role in processes, such as leukocyte adhesion and 
transmigration, proliferation, apoptosis, and cytokine expression 
(17–20). NO is generated by NO synthase (NOS) enzymes (21); 
neuronal NOS, constitutive eNOS, and inducible NOS (iNOS). 
NO production in inflammatory conditions and following infec-
tion is predominantly through iNOS (22).
The versatility of NO at inducing variable responses suggests 
it has both pro- and anti-inflammatory effects. However, the 
inhibition of NO pathways is often beneficial in the treatment 
of inflammatory disease (23). Several factors modify the effect 
of NO including its concentration, the rate of reactive nitrogen 
species formation and the physiological environment. During the 
inflammatory response, pro-inflammatory cytokines stimulate 
NO production in monocytes, macrophages, and neutrophils 
and in vivo levels can increase by up to 1,000-fold in severe cases 
of bacterial sepsis (22). NO acts as a positive feedback molecule 
when released by tissue macrophages during phagocytosis, lead-
ing to the recruitment of further phagocytes. However, excessive 
NO can lead to tissue destruction as seen in autoimmune diseases 
(24). The level of NO produced is regulated at the transcriptional 
level, depending on the cell type and the nature of the stimulation 
involved. The mitogen-activated protein kinase and PI3 kinase 
pathways mediate NO production (25) but there is conflicting 
evidence if the p38 pathway is involved, with studies showing 
upregulation, downregulation, and no effect on NO production 
(26, 27). NO can also regulate its own production via positive 
and negative feedback loops. The positive feedback utilizes the 
increase in cAMP levels to activate the production of iNOS and 
subsequent increase in NO production. The negative feedback 
loop uses the inhibition of NFκβ to lower NO production (25).
Several studies that have highlighted a relationship between 
NO production and CRP. Hattori et al. (28) showed CRP mediates 
both NO and iNOS gene expression. Schwedler et al. (21) found 
that nCRP treatment in vivo caused impairment in endothelial 
function in the aortic rings that was associated with increased 
iNOS activity. Several cardiovascular studies have revealed that 
nCRP inhibits NO production by downregulating endothelial 
NOS (eNOS) in endothelial cells, thereby inhibiting angiogenesis 
(29). Inhibition of endothelial-derived NO promotes the patho-
genesis of atherosclerotic vascular disease through vaso constriction, 
leukocyte adherence, and inflammatory cell activation (29–32), 
highlighting the pro-inflammatory nature of nCRP in the circula-
tory system. Little work has been published on the effect of CRP 
on NO production by cells and tissues outside the cardiovascular 
system. Borderie et al. (33) showed that CRP concentration corre-
lates with the number of iNOS-positive synovial fluid leukocytes 
in patients with rheumatoid arthritis but specific CRP isoforms 
were not distinguished. The mCRP isoform has subsequently 
been shown to enhance NO production in isolated human neu-
trophils via upregulated NOS activity (34). Consequently, this 
study assessed whether CRP isoforms have distinct effects on 
iNOS and NO production by human-derived U937 monocytes/
macrophages.
Nitric oxide is also regulated by many endogenous factors 
including the steroid hormone estrogen (35). Estrogen is known 
to have beneficial effects during wound repair following tissue 
injury, accelerating healing, and reducing inflammation in both 
male and female humans (36, 37). Moreover, the profound 
decline in estrogen levels in the elderly is implicated in age-related 
impaired healing, leading to delayed repair with excessive inflam-
mation (38). Studies have shown that estrogen has the ability to 
stimulate NO production and vasodilation in the cardiovascular 
system by inducing eNOS (39). In contrast, Hassouna et al. (40) 
showed that the loss of estrogen following ovariectomy in a rat 
model of inflammation significantly increased levels of both CRP 
and iNOS, while subsequent estrogen supplementation reversed 
this effect. This study investigated whether exogenous estrogen 
can mediate CRP-induced NO production by human-derived 
U937 monocytes/macrophages in an in vitro model of aging.
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MaTerials anD MeThODs
Purification of crP isoforms
The CRP isoforms were purified from a high purity commercial 
source of human nCRP (MBS536586; MyBioSource, San Diego, 
CA, USA). Purified mCRP was generated using the Potempa 
method (41). In this method, 1 ml commercial CRP protein was 
chelated in a 1:1 ratio with EDTA/urea buffer (10  mM EDTA, 
8 M ultrapure urea) and incubated at 37°C for 2 h prior to dialysis 
(20 kDa MWCO) in buffer (25 mM Tris–HCl, 50 mM NaCl; 
pH 8.3) for 24 h.
Commercial nCRP (1 ml) was purified further by hydrophobic 
interaction chromatography using a Sepharose HiTrap column 
(GE Healthcare, Buckinghamshire) according to the manufac-
turer’s instructions. The eluted protein was immediately placed 
inside a 50  kDa MWCO float-a-lyzer (Medicell, London) and 
dialyzed overnight into a 2 mM calcium chloride buffer (2 mM 
CaCl2, 25 mM Tris–HCl, 150 mM NaCl; pH 7.4).
Both the nCRP and mCRP samples were tested for purity 
by immunoblotting using published methods (42). The immu-
noblotting procedure consisted of placing 5 µl of purified CRP 
samples onto two separate nitrocellulose membranes. A similar 
volume blot (5 µl) of 1 mg/ml bovine serum albumin (BSA) was 
used as a negative control protein and 5 µl of the original com-
mercial CRP at 5 mg/ml was used as a positive control on each 
membrane. The samples were allowed to dry before placing the 
membranes in blocking buffer (1% BSA in TBS-Tween, pH 7.4) 
for 1 h at room temperature with 60 rpm rotation. Monoclonal 
mouse anti-human nCRP 1D6 [clone I-15-1D6 (isotype: IgG2a, κ)] 
and monoclonal mouse anti-human mCRP 8C10 [clone III-
26-8C10 (IgG1, κ)] were primary antibodies kindly provided by 
L.A. Potempa (Roosevelt University, IL, USA; ImmTech Inc.) to 
detect specific CRP isoforms (43). Membranes were incubated 
overnight at 5°C with 50 rpm rotation in primary antibody diluted 
1:10 with blocking buffer before washing five times in TBS-Tween 
buffer for 5 min. The membranes were then incubated in a 1:1,000 
dilution of horseradish peroxidase (HRP)-conjugated polyclonal 
rabbit anti-mouse immunoglobulins (secondary antibody) 
(P0260; Dako, Cambridge) in 5% milk/TBS-tween solution for 
1  h with 60  rpm rotation. The membranes were washed again 
five times in TBS-Tween buffer for 5 min. The membranes were 
then treated with the EZ-ECL chemiluminescence detection kit 
for HRP (K1-0172; Geneflow, Lichfield) according to the manu-
facturer’s instructions. The chemiluminescent image was then 
captured in a Syngene GBox with a 1 min exposure time using 
Genesnap software (Version 7.07, Syngene).
Purified CRP samples were quantified using bicinchronic acid 
(BCA) analysis (BCA1-1KT; Sigma-Aldrich, Poole) according 
to the manufacturer’s instructions to determine the yield. A 
standard curve was generated for the BCA analysis using a BSA 
standard. CRP samples were incubated with BCA working buffer 
for 30 min at 37°C prior to reading absorbance measurements at 
595 nm on a Biotech Synergy HT plate reader. CRP concentra-
tions were quantified by interpolation from the standard curve 
and then normalized at 2  mg/ml. Normalized CRP samples 
(2 mg/ml) were then sterile filtered and confirmed endotoxin-free 
using a commercial endotoxin detection E-TOXATE (Limulus 
amebocyte lysate) kit (ET0100; Sigma Aldrich, Poole) according 
to the manufacturer’s instructions. All CRP isoforms were stored 
at 4oC until use in cell assays.
cell culture
The monocyte-like cell line U937 was cultured in RPMI-1640 media 
supplemented with 10% FBS and 2% penicillin–streptomycin. 
In some experiments, U937 cells were differentiated into a 
macrophage-like phenotype using 50 ng/ml phorbol 12-myristate 
13-acetate (PMA) for 72  h and/or pre-activated for 24  h with 
0.5 mg/ml lipopolysaccharide (LPS). All cell culture experiments 
were performed in a class II safety cabinet according to local 
biosecurity and safety procedures. Figure 1 outlines the different 
treatment paths used to activate and differentiate the U937 cells. 
Cell viability was assessed using 0.4% trypan blue exclusion in 
which cellular uptake of the dye indicates cell death.
Flow cytometry
Differentiation of U937 monocytes into a macrophage-like phe-
notype was confirmed by flow cytometry through detection of the 
CD11c macrophage-specific surface antigen. Following differen-
tiation with PMA, cells were treated with 4% paraformaldehyde in 
Dulbecco’s phosphate-buffered saline (DPBS) for 10 min at room 
temperature. Cells were washed twice with DPBS and stained for 
30 min at room temperature with FITC-conjugated anti-human 
CD11c antibody (Clone Bu15; BioLegend, UK) diluted 1:40 with 
10% fetal bovine serum (FBS) in DPBS. Cells were then washed 
twice in DPBS before suspension in 500  µL DPBS. CD11c 
expression was assessed on 10,000 events (live, individual cells) 
with a BD Accuri C6F1 cytometer using BD Accuri C6 software 
(Biosciences, USA) after gating in the forward scatter/side scat-
ter and fluorescence parameter 1 (FL1-A) windows. Data were 
presented as average percentage CD11c+ cells (%) and median 
fluorescence intensity (MFI) relative to unstained monocytes 
from three independent experiments.
nO and inOs assays
Cells at a concentration of 1 × 106 cells/ml were incubated with 
physiological concentrations of mCRP (100 µg/ml or 250 µg/ml) 
or nCRP (500 µg/ml or 1,000 µg/ml) for 24 h. Negative controls 
were incubated with equivalent concentrations of BSA for 24 h. In 
inhibitor treatments, cells were co-incubated with CRP isoforms 
and the inhibitor nystatin at a concentration of 25 µg/ml. In the 
aging model, cells were co-incubated with CRP isoforms and 
estrogen at a concentration of 1 × 10−7, 1 × 10−8, and 1 × 10−9 M. 
Estrogen at 1 × 10−8 M is typical of physiological levels found in 
circulation during youth and a concentration range from 1 × 10−9 
to 1 × 10−7 M is frequently utilized under experimental condi-
tions (44, 45). Furthermore, cultured human inflammatory cells, 
including U937 cells, have previously been utilized as in  vitro 
models of estrogen-mediated aging (46, 47).
Nitric oxide production was measured in each treatment group 
(n = 12) by the Griess method (48) with the absorbance of a 1:1 
ratio of sample and Griess reagent read using a Biotech Synergy 
HT plate reader at a wavelength of 540 nm. Concentrations were 
calculated against a standard curve of sodium nitrite standards 
(0, 1, 10, 25, 50, 75, and 100 µM).
FigUre 1 | Flow chart of different treatment paths used to activate and differentiate the U937 cells. U937 cells were differentiated into a macrophage-like 
phenotype using 50 ng/ml phorbol 12-myristate 13-acetate (PMA) for 72 h and/or pre-activated for 24 h with 0.5 mg/ml lipopolysaccharide (LPS).
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The human iNOS sandwich-enzyme-linked immunosorb-
ent assay (Elabscience, USA) was used to measure iNOS levels 
in each treatment group (n = 12) according to the manufac-
turer’s instructions and published work (49). Optical density 
readings were performed using a Biotech Synergy HT plate 
reader at a wavelength of 450  nm and concentrations were 
calculated against the standard curve generated within the 
assay.
statistical analysis
Readings for NO and iNOS were measured in four replicate 
sample wells and average concentrations were determined from 
three independent experiments (n  =  12 in total). Treatment 
groups were analyzed by ANOVA and t-tests (parametric data) 
or Mann–Whitney U-tests (non-parametric data) using SPSS 
(Version 22). A probability (P) value of P < 0.05 was considered 
statistically significant in all cases.
resUlTs
Purification of crP isoforms
Immunoblotting confirmed the purity of CRP isoforms 
(Figure 2) used in the experiments. There was no detection of 
mCRP in the purified nCRP sample and no detection of nCRP 
in the purified mCRP sample. Purification yields for nCRP and 
mCRP were 4.5 and 2.3 mg/ml, respectively prior to normaliza-
tion at 2 mg/ml.
Moreover, both the nCRP and mCRP samples at 2 mg/ml were 
confirmed effectively endotoxin-free (<20 ρg/ml), thus excluding 
LPS contamination in the experimental treatments. In essence, 
the deliberate pre-activation of some U937 cells with 0.5 mg/ml 
LPS exposed those cells to at least 25 million times more endo-
toxin than was present in normalized CRP samples, and at least 
50 and 200 million times more endotoxin than was present in 
experimental concentrations of nCRP (<10  ρg/ml LPS) and 
mCRP (<2.5 ρg/ml LPS), respectively. Therefore, the negligible 
endotoxin levels in CRP treatments cannot account for observed 
experimental changes in NO.
Flow cytometry
The conversion of U937 monocytic cells into a distinct popula-
tion of macrophage was confirmed via detection of the CD11c 
surface marker by flow cytometry (Figure 3). PMA-differentiated 
cells almost exclusively (99.6% CD11c+) expressed the CD11c 
macrophage marker, whereas monocytes predominantly lacked 
the CD11c surface marker (0.2% CD11c+). The MFI was sig-
nificantly (P < 0.001) higher in PMA-treated cells compared to 
undifferentiated U937 monocytes, confirming PMA transformed 
U937 monocytes into CD11c+ macrophages.
The effect of exogenous crP isoforms  
on nO and inOs Production
The NO values obtained in the study were in line with published 
findings utilizing unstimulated and LPS-activated U937 cells 
FigUre 2 | Immunoblot confirming purity of C-reactive protein (CRP) isoforms. Immunoblotting confirmed the presence of monomeric CRP (mCRP) alone  
(a) and native CRP (nCRP) alone (B) in purified samples. Both membranes included blots for a non-specific bovine serum albumin negative control protein, the 
purified mCRP sample, the purified nCRP, and the original commercial CRP sample. The mCRP and nCRP isoforms were detected with monoclonal anti-mCRP 
8C10 [membrane (a)] and monoclonal anti-nCRP 1D6 [membrane (B)] respectively.
FigUre 3 | Flow cytometry confirming macrophage differentiation. The conversion of U937 monocytic cells into a distinct population of macrophage was confirmed 
via detection of the CD11c surface marker by flow cytometry (data represent an average of three independent experiments). Phorbol 12-myristate 13-acetate-
differentiated cells almost exclusively expressed the CD11c macrophage marker, whereas monocytes predominantly lacked the CD11c surface marker (a). Two 
distinct populations of cells were detected (B) with significantly higher median fluorescence intensity (MFI) in PMA-treated cells compared to undifferentiated U937 
monocytes (c). ***Indicates significant difference in MFI (P < 0.001; n = 3). Errors bars represent the SEM.
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(50–52). Monocytic cells exhibited a substantial (more than 
1.5-fold) concentration-dependent increase (P < 0.05) in NO and 
iNOS production when treated with mCRP (Figures 4A and 5A), 
regardless of their activation state. The mCRP isoform did not 
have any effect (P > 0.05) on NO or iNOS production by unacti-
vated or LPS-activated macrophages, whereas nCRP significantly 
FigUre 5 | Effect of C-reactive protein (CRP) isoforms on inducible nitric oxide synthase (iNOS). Levels of iNOS production by several cell states (monocyte, 
lipopolysaccharide (LPS)-activated monocyte, macrophage, and LPS-activated macrophage) were differentially mediated by CRP isoforms in a concentration-
dependent manner (a). Nystatin significantly reversed CRP-mediated iNOS production in unactivated monocytes treated with nCRP and activated monocytes 
treated with mCRP (B). *Indicates significant differences (P < 0.05; n = 12) in iNOS production compared with corresponding negative controls (a) or CRP/nystatin 
treatments (B). Errors bars represent the SEM.
FigUre 4 | Effect of C-reactive protein (CRP) isoforms on nitric oxide (NO) production. NO production by several cell states (monocyte, lipopolysaccharide 
(LPS)-activated monocyte, macrophage, and LPS-activated macrophage) was differentially mediated by CRP isoforms in a concentration-dependent manner  
(a). Nystatin significantly reversed CRP-mediated NO production in unactivated monocytes treated with native CRP (Ncrp) and activated monocytes treated with 
mCRP (B). *Indicates significant differences (P < 0.05; n = 12) in NO production compared with corresponding negative controls (a) or CRP/nystatin treatments  
(B). Errors bars represent the SEM.
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(P < 0.05) reduced NO and iNOS production by both unactivated 
and LPS-activated macrophages. However, the greatest reduction 
in NO (from 13.7 to 6.5 µM) and iNOS (from 19.6 to 5.1ρg/ml) 
was observed by LPS-activated monocytes following treatment 
with (1,000 µg/ml) nCRP. Interestingly, the nCRP isoform had the 
opposite effect in unactivated monocytes, significantly (P < 0.05) 
increasing NO and iNOS following treatment with nCRP, but 
more modestly than the mCRP isoform.
The effect of nystatin on crP-induced  
nO and inOs Production
Sample treatments that exhibited significant changes in NO pro-
duction were repeated with the nystatin inhibitor to determine 
whether the CRP-mediated responses involved interaction with 
lipid rafts in the cellular membrane of monocytes/macrophages. 
Figures  4B and 5B show significant reversal of NO and iNOS 
production following inhibition with nystatin. Non-significant 
FigUre 6 | Effect of estrogen on nitric oxide (NO) production. Estrogen reduced NO production by lipopolysaccharide (LPS)-activated U937 monocytes and 
macrophages. * denotes a significant (P < 0.05; n = 12) difference in NO production followed by treatment with estrogen (1 × 10−7 1 × 10−8, or 1 × 10−9 M) 
compared to the negative control. Errors bars represent the SEM.
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results (P  >  0.05) were excluded from Figures  4B and 5B for 
clarity, including treatment with nystatin alone (NO = 12.3 ± 0.4 
and 12.9 ± 0.4 μM; iNOS = 18.3 ± 1.5 and 20.0 ± 1.0 ρg/ml in 
unactivated and activated monocytes respectively).
When unactivated monocytes were treated with nCRP there 
was a significant increase (P  <  0.05) in the production of NO 
and iNOS. When co-treated with nystatin there was a significant 
reversal in both NO (P = 0.001) and iNOS (P < 0.001) production 
by unactivated monocytes treated with 1,000 µg/ml nCRP.
Treatment of LPS-activated monocytes with mCRP induced 
a significant (P < 0.001) increase in NO and iNOS production. 
Again, nystatin significantly reversed the mCRP-induced NO 
(P < 0.05) and iNOS (P < 0.001) production by LPS-activated 
monocytes back to levels observed in the corresponding control.
The effect of estrogen on crP-induced 
nitric Oxide Production
Treatment with estrogen controls in the absence of CRP isoforms 
(Figure 6) showed that physiological concentrations of estrogen 
reduced NO production by monocytes and macrophages exposed 
to endotoxin. Treatment of unactivated monocytes with either 
CRP isoform alone significantly (P < 0.001) increased NO produc-
tion. However, all concentrations of estrogen co-supplementation 
significantly decreased (P < 0.01) CRP-induced NO production 
by unactivated monocytes (Figure 7) to levels similar or below 
those of the untreated control. Moreover, the reduction in NO 
by LPS-activated monocytes following treatment with estrogen 
alone (in the absence of CRP isoforms) was relatively modest 
compared to the estrogen-mediated reversal of NO production 
following co-incubation with mCRP.
Similar to the response by unactivated monocytes, mCRP sig-
nificantly (P < 0.001) increased NO production by LPS-activated 
monocytes. In direct contrast, there was a significant (P < 0.01) dose-
dependent decrease in NO production by LPS-activated monocytes 
following treatment with nCRP. Estrogen significantly (P < 0.05) 
reversed mCRP-induced NO production to levels below that of the 
control while having no effect on the nCRP-mediated inhibition 
of NO production by LPS-activated monocytes (Figure 8).
Estrogen had no significant (P  >  0.05) effect on NO pro-
duction when co-supplemented with mCRP in unactivated 
(Figures 9A,B) and LPS-activated (Figures 10A,B) macrophages, 
mirroring the fact treatment with mCRP alone had no significant 
effect on NO production by macrophages.
The nCRP isoform significantly reduced NO production 
by unactivated and LPS-activated macrophages. Estrogen 
significantly reversed (P < 0.01) the nCRP-mediated reduction 
in NO production by unactivated macrophages treated with 
low  (Figure  9C) but not high  (Figure  9D) levels of nCRP. 
Co-incubation with estrogen maintained the nCRP-mediated 
reduction in NO production by LPS-activated macrophages 
(Figures  10C,D), in line with modest reductions in NO fol-
lowing treatment with estrogen alone (in the absence of CRP 
isoforms).
FigUre 7 | Effect of estrogen on C-reactive protein (CRP)-mediated nitric oxide (NO) production by unactivated U937 monocytes. Estrogen reversed CRP-induced 
NO production by unactivated U937 monocytes (a–D). −/− represents the untreated negative control with no CRP or estrogen supplementation. +/− represents 
treatment with CRP alone. +/+ represents treatment with both CRP and estrogen. The number in parentheses indicates the concentration (1 × 10−7, 1 × 10−8, or 
1 × 10−9 M) of estrogen. *Denotes a significant (P < 0.05; n = 12) difference in NO production following treatment with CRP or co-supplementation with estrogen. 
Errors bars represent the SEM.
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DiscUssiOn
The effect of exogenous crP isoforms  
on nO Production
The response to each CRP isoform appeared to be dependent 
on the differentiation and activation status of cells. The mCRP 
isoform stimulated NO and iNOS production by monocyte-like 
U937 cells, regardless of the activation state. This agrees with 
studies showing CRP can induce NO production in both the 
presence and absence of infection (28, 53). The mCRP isoform 
has previously been shown to stimulate NO production in 
neutrophils (34). In stark contrast, the nCRP isoform reduced 
NO and iNOS production by macrophage-like cells, both in 
the presence and absence of endotoxin. Furthermore, in LPS-
activated monocytes, nCRP reduced NO and iNOS levels in 
a concentration-dependent manner. These findings support 
growing evidence that nCRP often has opposing actions to 
mCRP and dampens the overall inflammatory response relative 
to that induced by mCRP following tissue injury or infection 
(54, 55).
Collectively, these findings suggest that CRP isoforms medi-
ate NO levels in U937 monocytes/macrophage via changes in 
the levels of iNOS. Previous work has also showed that CRP can 
mediate NO production in cardiac myocytes via iNOS (53) but 
responses to each specific CRP isoform were not determined. 
The data indicate that nCRP may have an inhibitory effect on 
NO and iNOS production by circulating monocytes following 
activation by bacterial endotoxin, and by tissue macrophages 
with or without prior LPS-activation. In direct contrast, the 
data suggest mCRP may have a stimulatory effect on NO and 
iNOS production by circulating monocytes with or without 
prior activation by bacterial endotoxin but this effect is lost once 
monocytes differentiate into tissue macrophages. In the absence 
of infection, the findings indicate both nCRP and mCRP increase 
NO and iNOS production by monocytes but the stimulation by 
nCRP is relatively modest compared to that produced by mCRP 
at CRP concentrations typical of an acute inflammatory response. 
The relative proportion of each CRP isoform in vivo could pos-
sibly influence the inflammatory response generated, with the 
formation of mCRP from the dissociation of nCRP promoting 
FigUre 8 | Effect of estrogen on C-reactive protein (CRP)-mediated nitric oxide (NO) production by lipopolysaccharide (LPS)-activated U937 monocytes. 
Estrogen reversed monomeric CRP (mCRP)-induced NO production (a,B) but had no effect on native CRP (Ncrp)-mediated inhibition of NO production (c,D) 
by activated U937 monocytes. −/− represents the untreated negative control with no CRP or estrogen supplementation. +/− represents treatment with CRP 
alone. +/+ represents treatment with both CRP and estrogen. The number in parentheses indicates the concentration (1 × 10−7, 1 × 10−8, or 1 × 10−9M) of 
estrogen. *Denotes a significant (P < 0.05; n = 12) difference in NO production following treatment with CRP or co-supplementation with estrogen. Errors bars 
represent the SEM.
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inflammation. Elevated levels of NO are known to induce the 
production of pro-inflammatory cytokines (56) including IL-6 
and tumor necrosis factor alpha (TNF-α) by both monocytes/
macrophages (57, 58) and neutrophils (59). The release of such 
cytokines can stimulate iNOS, leading to further NO production 
(60) and increased phagocytosis (61).
effect of nystatin on crP-induced  
nO Production
Nystatin was the only inhibitor applied in this study. Several 
other inhibitors had been considered but could not be utilized, 
since they directly affect NO production (62–64). Nystatin is a 
relatively mild inhibitor that binds to cholesterol and disassem-
bles lipid rafts in cellular membranes (65). The mCRP isoform is 
known to associate with lipid rafts in the cell membranes (13, 66).
In this study, nystatin reversed nCRP-induced NO and iNOS 
production by unactivated monocytes and mCRP-induced NO 
and iNOS production by LPS-activated monocytes. Thus, given 
nystatin disrupts lipid rafts and these findings suggest nCRP may 
interact with lipid rafts in monocytes in the absence of infection, 
whereas mCRP may associate with lipid rafts in monocytes 
following infection. Given the binding of mCRP to integrins 
αvβ3 and α4β1 influences its pro-inflammatory actions (67), 
antagonizing these integrins may help to elucidate mechanisms 
by which mCRP mediates NO production.
In both unactivated and activated macrophages, nystatin had 
no significant (P > 0.05) effect on the nCRP-mediated reduction 
in NO and iNOS. This suggests that once monocytes become 
mature macrophages, nCRP might no longer associate with lipid 
rafts. The mCRP isoform had no effect on NO or iNOS production 
by macrophages in the presence or absence of LPS, so nystatin 
inhibition was irrelevant.
Treatment of U937 monocytes and macrophages with nysta-
tin alone had no significant effect on NO levels, suggesting this 
inhibitor did not directly disrupt NO pathways through its effect 
on cell membranes. Indeed, nystatin has been routinely utilized in 
various investigations of CRP activity and studies have confirmed 
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it does not cause a functional disturbance of cellular cholesterol 
homeostasis (13, 68).
effect of estrogen on crP-induced  
nO Production
Physiological concentrations of estrogen had distinct effects 
on CRP-mediated NO production, dependent on cell differen-
tiation and activation state, agreeing with studies showing that 
estrogen can have both suppressive and stimulatory effects on 
iNOS and NO production (35). The decrease in CRP-induced 
NO levels by estrogen in unactivated monocytes treated with 
nCRP or mCRP supports evidence showing estrogen reduces the 
inflammatory response, including the production of NO/iNOS 
(37, 40). Estrogen reversed mCRP-induced NO production by 
LPS-activated monocytes, while the nCRP-mediated reduction in 
NO production was maintained by physiological concentrations 
of estrogen in LPS-activated monocytes. This supports previous 
work showing estrogen suppresses pro-inflammatory effects, 
including NO production (69, 70) and inflammatory cytokines 
such as IL-6 in activated monocytes (71). Indeed, treatment of 
LPS-activated monocytes with estrogen in the absence of CRP 
also reduced NO levels but the reduction was modest compared 
to the estrogen-mediated reversal of NO production following 
treatment with mCRP.
In both unactivated and LPS-activated macrophages, nCRP 
significantly decreased NO production, indicative of the relative 
anti-inflammatory properties of nCRP in tissues (11). Reversal 
of the nCRP-mediated reduction in NO production by estrogen 
in unactivated macrophages concurs with findings showing 
increased iNOS expression and NO production by peritoneal 
macrophages and splenocytes exposed to estrogen (35, 72). 
Furthermore, some studies have shown that estrogen can induce 
interferon-gamma (IFN-γ) secretion and subsequent NO produc-
tion by macrophages (35, 73, 74). The nCRP-induced reduction 
in NO by activated macrophages was sustained by physiological 
concentrations of estrogen, concurring with the reduction in NO 
production following treatment of LPS-activated macrophages 
with estrogen in the absence of CRP isoforms. These findings 
agree with recent evidence showing estrogen reduces the inflam-
matory response, including NO production, in LPS-activated 
macrophages (75).
FigUre 9 | Effect of estrogen on CRP-mediated NO production by unactivated U937 macrophages. Estrogen had no effect on NO production when  
co-supplemented with mCRP in unactivated (a,B) macrophages. However, estrogen reversed the nCRP-mediated reduction in NO production by unactivated 
macrophages treated with low (c) but not high (D) levels of nCRP. −/− represents the untreated negative control with no CRP or estrogen supplementation. 
+/− represents treatment with CRP alone. +/+ represents cells treatment with both CRP and estrogen. The number in parentheses indicates the concentration 
(1 x 10−7, 1 x 10−8, or 1 x 10−9M) of estrogen. * denotes a significant (P < 0.05; n = 12) difference in NO production following treatment with nCRP or  
co-supplementation with estrogen. Errors bars represent the SEM.
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cOnclUsiOn
In conclusion, the findings suggest that CRP isoforms are poten-
tial targets for mediating NO production by human monocytes 
and macrophages. Each CRP isoform induced a distinct profile 
of NO responses that was dependent on cell differentiation and 
activation status. In the presence or absence of endotoxin, nCRP 
had an inhibitory effect on NO/iNOS production in macrophages 
whereas mCRP had no effect. The mCRP had a stimulatory 
effect on NO/iNOS synthesis in monocytes, with or without 
LPS-activation. The nCRP isoform had opposing effects in mono-
cytes, reducing NO/iNOS production following LPS-activation 
but stimulating NO by unactivated monocytes. These findings 
warrant further investigation to confirm the results in additional 
cell lines and ex vivo primary human leukocytes, together with 
the use of selective inhibitors to elucidate the pathways involved. 
Animal models of age-related impaired healing could assess the 
effect of CRP isoforms on in vivo NO production during aging. 
The predominant inhibition of NO/iNOS production by nCRP in 
all cell states except unactivated monocytes and the stimulation 
of NO/iNOS by mCRP in monocytes supports growing evidence 
that mCRP initiates a greater inflammatory response relative 
to nCRP. Furthermore, the findings highlight the importance 
of the age-related decline in hormones (notably estrogen) on 
CRP-mediated responses and have implications for therapeu-
tic strategies aimed at the elderly. With the exception of NO 
stimulation by estrogen in unactivated macrophages treated with 
nCRP, the predominant reduction of CRP-induced NO levels by 
estrogen supports evidence that estrogen reduces the inflamma-
tory response following injury and infection. Thus, therapeutic 
strategies that restore estrogen levels to those found in youth and 
promote the stability of nCRP and/or prevent the formation of 
mCRP from the dissociation of nCRP may reduce overall NO 
production in age-related inflammatory conditions.
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